CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRVO CervoMed

Post-Market Trading 01-08 18:59:03 EST

2.18

-0.13

-5.63%

盘后2.16

-0.02-0.92%

17:22 EST

High2.30	Low2.16	Vol145.35K
Open2.30	D1 Closing2.31	Amplitude6.06%
Mkt Cap17.99M	Tradable Cap8.90M	Total Shares8.25M
T/O320.89K	T/O Rate3.56%	Tradable Shares4.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":2.18,"timestamp":1736370000000,"preClose":2.31,"halted":0,"volume":145350,"hourTrading":{"tag":"盘后","latestPrice":2.16,"preClose":2.18,"latestTime":"17:22 EST","volume":1506,"amount":3310.4349839999995,"timestamp":1736374959453},"delay":0,"floatShares":4082396,"shares":8253741,"eps":-1.600656,"marketStatus":"Post-Market Trading","change":-0.13,"latestTime":"01-08 18:59:03 EST","open":2.3,"high":2.3,"low":2.16,"amount":320894.74737,"amplitude":0.060606,"askPrice":2.25,"askSize":8287,"bidPrice":2.16,"bidSize":247,"shortable":3,"etf":0,"ttmEps":-1.600656,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1736384400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":2.31,"preHourTrading":{"tag":"盘前","latestPrice":2.26,"preClose":2.31,"latestTime":"09:25 EST","volume":392,"amount":903.2428328,"timestamp":1736346358000},"postHourTrading":{"tag":"盘后","latestPrice":2.16,"preClose":2.18,"latestTime":"17:22 EST","volume":1506,"amount":3310.4349839999995,"timestamp":1736374959453},"volumeRatio":0.507552},"requestUrl":"/m/hq/s/CRVO/wiki","defaultTab":"wiki","newsList":[{"id":"2492952296","title":"HC Wainwright Downgrades CervoMed to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2492952296","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492952296?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:31","pubTimestamp":1734442275,"startTime":"0","endTime":"0","summary":"HC Wainwright Downgrades CervoMed to Neutral From Buy","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRVO"],"gpt_icon":0},{"id":"2492959818","title":"EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2492959818","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492959818?lang=en_us&edition=fundamental","pubTime":"2024-12-17 20:00","pubTimestamp":1734436800,"startTime":"0","endTime":"0","summary":"EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA (aflibercept) Injection 2 mg dosed every 4 weeks Safety data remains consistent with the known EYL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998107/0/en/EYLEA-HD-aflibercept-Injection-8-mg-Phase-3-Trial-Meets-Primary-Endpoint-Showing-Improved-Vision-with-Extended-Dosing-Intervals-in-Patients-with-Macular-Edema-following-Retinal-Vei.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRVO","LU0868494708.USD","LU2362541273.HKD","BK4504","LU1069344957.HKD","LU1093756168.USD","LU1316542783.SGD","REGN","IE00BSNM7G36.USD","LU0642271901.SGD","BK4581","LU1989764664.SGD","LU0053666078.USD","LU1633808545.USD","ROP","BK4573","IE00B1XK9C88.USD","IE00BMPRXR70.SGD","LU0082616367.USD","LU0234572021.USD","LU2264538146.SGD","LU1712237335.SGD","LU0354030511.USD","BK4139","LU0114720955.EUR","LU0127658192.USD","LU2250418816.HKD","HD","LU1551013425.SGD","BK4529","LU2362540622.SGD","LU0823421333.USD","LU1496350171.SGD","BK4588","IE0004445239.USD","BK4575","LU0289739699.SGD","BK4206","LU0868494617.USD","LU0719512351.SGD","LU0320765646.SGD","LU2362541513.USD","BK4567","LU1951200564.SGD","CRVO","LU0056508442.USD","IE0009356076.USD"],"gpt_icon":1},{"id":"2492972958","title":"CervoMed Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492972958","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492972958?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:34","pubTimestamp":1734435240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2024 06:34 ET (11:34 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2492305349","title":"CervoMed (CRVO) was downgraded to a Hold Rating at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2492305349","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492305349?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:16","pubTimestamp":1734434201,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO – Research Report) received a Hold rating and price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares cl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cervomed-crvo-was-downgraded-to-a-hold-rating-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cervomed-crvo-was-downgraded-to-a-hold-rating-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2492303169","title":"CervoMed downgraded to Neutral from Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2492303169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492303169?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:16","pubTimestamp":1734434190,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Raghuram Selvaraju downgraded CervoMed (CRVO) to Neutral from Buy without a price target saying the “disappointing” neflama...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-downgraded-to-neutral-from-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-downgraded-to-neutral-from-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2492937418","title":"CervoMed Inc : H.c. Wainwright Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2492937418","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492937418?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:07","pubTimestamp":1734433651,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nAZN2UXX5L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2490438817","title":"CervoMed price target lowered to $4 from $45 at Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2490438817","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490438817?lang=en_us&edition=fundamental","pubTime":"2024-12-12 20:45","pubTimestamp":1734007521,"startTime":"0","endTime":"0","summary":"Roth MKM lowered the firm’s price target on CervoMed  to $4 from $45 and keeps a Buy rating on the shares. The company has reported negative top-line results from the Phase 2b RewinD-LB – dementia with Lewy bodies – study of neflamapimod in pure DLB patients, raising questions about the program’s viability, the analyst tells investors in a research note. A potential reason for failure could be the drug’s inability to achieve the desired plasma concentration – a proxy for efficacy – and CervoMed is pausing Phase 3 preparations, originally scheduled to begin in the second half of FY25, the firm added.Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks. CervoMed downgraded to Underweight from Overweight at Morgan Stanley. CervoMed downgraded to Neutral from Buy at Chardan. CervoMed downgraded to Hold from Buy at JonesResearch","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zzQJwVxfC_2TzhvJl13Lkg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/6e60166f16c98d232e4fe2b08fd8a093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zzQJwVxfC_2TzhvJl13Lkg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/6e60166f16c98d232e4fe2b08fd8a093"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cervomed-price-target-lowered-4-124521466.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cervomed-price-target-lowered-4-124521466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRVO"],"gpt_icon":0},{"id":"2490080242","title":"CervoMed announces inducement grants under Nasdaq lisitng rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2490080242","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490080242?lang=en_us&edition=fundamental","pubTime":"2024-12-12 20:10","pubTimestamp":1734005409,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) has granted equity awards as a material inducement to the employment of two new employees. On December 6, 2024, the Company granted...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-announces-inducement-grants-under-nasdaq-lisitng-rule?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-announces-inducement-grants-under-nasdaq-lisitng-rule?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["USJW.SI","MNQmain","QID","TSYW.SI","IE00B3QW5Z07.USD","PSQ",".IXIC","USAW.SI","SQQQ","IE00BKPKM429.USD","NVIW.SI","LU2095319765.USD","QLD","CRVO","NQmain","LU2210150020.SGD","BK4588","BK4112","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","TQQQ","BK4585","IE00BGHQF748.EUR","BK4139"],"gpt_icon":0},{"id":"2490042718","title":"CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2490042718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490042718?lang=en_us&edition=fundamental","pubTime":"2024-12-12 20:00","pubTimestamp":1734004801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUA8FFV2K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B3QW5Z07.USD","BK4585","IE00BGHQF748.EUR","LU2095319765.USD","BK4588","LU2210150020.SGD","NDAQ","IE00BKPKM429.USD","CRVO","IE00B64PRP62.GBP","BK4112","LU2210149790.SGD","BK4139"],"gpt_icon":0},{"id":"2490802392","title":"CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2490802392","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490802392?lang=en_us&edition=fundamental","pubTime":"2024-12-12 20:00","pubTimestamp":1734004800,"startTime":"0","endTime":"0","summary":"BOSTON, Dec. 12, 2024  -- CervoMed Inc.  , a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has granted equity awards as a material inducement to the employment of two new employees.On December 6, 2024, the Company granted options to purchase an aggregate of 14,753 shares of common stock to two new employees. Each option has an exercise price of $11.91, the closing price of the Company’s common stock on the grant date, and each will vest in 36 equal installments on the last day of each month over a three-year period, subject to the employee’s continued employment with the Company on each such date. The awards were approved by the Compensation Committee of the Company’s Board of Directors as an inducement material to each new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xD1TTTZoqyWtGhy773ezlw--~B/aD0xMjc7dz00MTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/385dc1ddc05fe2c5223b5b9ca399d0fc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xD1TTTZoqyWtGhy773ezlw--~B/aD0xMjc7dz00MTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/385dc1ddc05fe2c5223b5b9ca399d0fc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cervomed-announces-inducement-grants-under-120000425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210150020.SGD","NDAQ","PHH","CRVO","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","BK4588",".IXIC","IE00B64PRP62.GBP","WRD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4585","BK4139","LU2210149790.SGD"],"gpt_icon":0},{"id":"2490200859","title":"Morgan Stanley Downgrades CervoMed to Underweight From Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2490200859","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490200859?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:57","pubTimestamp":1733921823,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) has an average rating of overweight and mean price target of $39.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRVO"],"gpt_icon":0},{"id":"2490834245","title":"CervoMed downgraded to Underweight from Overweight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2490834245","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490834245?lang=en_us&edition=fundamental","pubTime":"2024-12-11 18:35","pubTimestamp":1733913320,"startTime":"0","endTime":"0","summary":"Morgan Stanley double downgraded CervoMed (CRVO) to Underweight from Overweight without a price target saying multiple questions remain for neflama...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-downgraded-to-underweight-from-overweight-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-downgraded-to-underweight-from-overweight-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2490314768","title":"Morgan Stanley downgrades CervoMed (CRVO) to a Sell","url":"https://stock-news.laohu8.com/highlight/detail?id=2490314768","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490314768?lang=en_us&edition=fundamental","pubTime":"2024-12-11 18:17","pubTimestamp":1733912242,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO – Research Report) received a Sell rating and price target from Morgan Stanley analyst Jeffrey Hung today. The company’s shares clos...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-downgrades-cervomed-crvo-to-a-sell?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-downgrades-cervomed-crvo-to-a-sell?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2490030900","title":"CervoMed downgraded to Neutral from Buy at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2490030900","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490030900?lang=en_us&edition=fundamental","pubTime":"2024-12-11 10:15","pubTimestamp":1733883315,"startTime":"0","endTime":"0","summary":"Chardan downgraded CervoMed (CRVO) to Neutral from Buy without a price target after the company announced topline data from the Phase 2b RewinD-LB ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-downgraded-to-neutral-from-buy-at-chardan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-downgraded-to-neutral-from-buy-at-chardan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2490415025","title":"Sector Update: Health Care Stocks Decline Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2490415025","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490415025?lang=en_us&edition=fundamental","pubTime":"2024-12-11 04:53","pubTimestamp":1733864035,"startTime":"0","endTime":"0","summary":"Health care stocks were softer late Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each easing 0.2%.The iShares Biotechnology ETF (IBB) shed 0.6%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WBA.AU","BK4128","BK4139","BK4588","BK4581","CMRX","LU0321505439.SGD","IBB","LU0321505868.SGD","QURE","CRVO","BK4583","BK4585","WBA","XLV"],"gpt_icon":0},{"id":"2490600042","title":"Sector Update: Health Care Stocks Softer Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2490600042","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490600042?lang=en_us&edition=fundamental","pubTime":"2024-12-11 02:53","pubTimestamp":1733856801,"startTime":"0","endTime":"0","summary":"Health care stocks fell Tuesday afternoon, with the NYSE Health Care Index shedding 0.4% and the Health Care Select Sector SPDR Fund  down 0.2%.The iShares Biotechnology ETF  dropped 0.4%.In corporate news, Walgreens Boots Alliance  shares surged 20%. The company is in talks to be acquired by private equity firm Sycamore Partners, The Wall Street Journal reported, citing people familiar with the matter.The Supreme Court of Ohio ruled Tuesday that a state law abrogates Trumbull County and Lake County's common-law claims that Walmart , CVS Health  and Walgreens created a public nuisance \"by filling prescriptions for opioids without controls in place to stop the distribution of those that were illicitly prescribed.\" Walmart shares added 0.6%, and CVS fell 1.3%.CervoMed  shares plunged 76% after the company said a phase 2b trial assessing neflamapimod to treat people with dementia with Lewy bodies failed to meet its primary or key secondary endpoints.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1267930490.SGD","LU2430703178.SGD","WMT","LU1571399168.USD","LU1035773651.USD","LU1066051498.USD","IE0034235188.USD","LU1064131342.USD","LU2361044949.HKD","LU0289960550.SGD","LU1280957306.USD","BK4550","LU1116320737.USD","LU2592432038.USD","LU0417517546.SGD","CVS.AU","LU0321505439.SGD","LU0211328371.USD","BK4597","LU1366192091.USD","XLV","LU0208291251.USD","LU0265550359.USD","IBB","BK4504","LU2360032135.SGD","WBA","LU2505996681.GBP","LU0211327993.USD","CVS","LU1066051811.HKD","LU1814569148.SGD","LU0006061336.USD","LU0061475181.USD","LU1116320901.HKD","CRVO","LU0321505868.SGD","BK4196","BK4533","LU2125154778.USD","WBA.AU","LU2361045086.USD","LU2125154935.USD","LU2461242641.AUD","LU1059921491.USD","BK4139","LU1988902786.USD","BK4588","LU2264538146.SGD","LU0162691827.USD"],"gpt_icon":1},{"id":"2490569042","title":"BUZZ-U.S. STOCKS ON THE MOVE-CoreCivic, Alphabet, Vail Resorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2490569042","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490569042?lang=en_us&edition=fundamental","pubTime":"2024-12-11 02:46","pubTimestamp":1733856405,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-CoreCivic, Alphabet, Vail ResortsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nL4N3NB10I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTVE","IAC","NOV","LU2133065610.SGD","UNFI","SEI","DBI","VSCO","CRDF","CXW","NCLH","REGN","ASO","EBAY","MATW","PINS","UPS","NEM","LU0640476718.USD","LU1571399168.USD","CRVO","ORCL","SLB","WBA","LU1935042991.SGD","LU1712237335.SGD","IE0002270589.USD","AJG","VNCE","JOUT","LU0345780281.USD","TARA","LU1721427968.SGD","GIII","IE00BWXC8680.SGD","HAL","AMGN","IE00B1XK9C88.USD","LU0353189763.USD","TOL","CFG","OLLI","FERG","KMI","MTN"],"gpt_icon":1},{"id":"2490604173","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2490604173","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490604173?lang=en_us&edition=fundamental","pubTime":"2024-12-11 02:14","pubTimestamp":1733854462,"startTime":"0","endTime":"0","summary":"CervoMed  said Tuesday that a phase 2b trial assessing neflamapimod to treat people with dementia with Lewy bodies failed to meet its primary or key secondary endpoints.Shares slumped 77% as intraday trading volume soared to over 6.44 million from a daily average of about 122,000.MEDIROM Healthcare Technologies  shares tumbled 45% amid heavy trading after the company unveiled late Monday an offering of 2.86 million American Depositary Shares at $1.75 each, targeting gross proceeds of about $5 million.More than 1.51 million shares traded intraday compared with a daily average of about 117,000.Biora Therapeutics  said in a regulatory filing Tuesday that Nasdaq has determined to delist its securities for failing to comply with the market value of listed securities requirement.Shares sank 60%, with intraday trading volume at over 1.39 million versus a daily average of about 88,000.Price: 2.36, Change: -7.89, Percent Change: -76.98","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MRM.AU","BIOR","BK4196","BK7108","CRVO","BK4139","BK4192","MRM"],"gpt_icon":0},{"id":"2490461000","title":"CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets","url":"https://stock-news.laohu8.com/highlight/detail?id=2490461000","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490461000?lang=en_us&edition=fundamental","pubTime":"2024-12-11 00:37","pubTimestamp":1733848634,"startTime":"0","endTime":"0","summary":"On Tuesday, CervoMed Inc. stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies .The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes  or any of its key secondary endpoints – change from baseline in Timed Up and Go  test, change from baseline in a Neuropsychological Test Battery , and the Clinician’s Global Impression of Change .Initial analysis shows that target plasma drug concentrations were not achieved during the double-blind phase of the trial, which may have adversely impacted trial results.In the RewinD-LB Phase 2b trial, neflamapimod demonstrated a favorable safety and tolerability profile consistent with prior clinical studies, with no new safety signal identified.This article CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets originally appeared on Benzinga.com. 2024","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YIq_ni4KPuFL1dZCsnks.w--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/6a865aa26bcc8c98f3ad9b5c20803f0a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YIq_ni4KPuFL1dZCsnks.w--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/6a865aa26bcc8c98f3ad9b5c20803f0a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cervomeds-dementia-candidate-fails-mid-163714409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4097","LU0345774391.USD","SSI","CRVO","LU0348723411.USD","DLB","LU0240877869.USD","LU0240878834.USD","LU0345774631.USD","LU0205194284.USD","LU0205193047.USD"],"gpt_icon":0},{"id":"2490488610","title":"CervoMed downgraded to Hold from Buy at Brookline","url":"https://stock-news.laohu8.com/highlight/detail?id=2490488610","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490488610?lang=en_us&edition=fundamental","pubTime":"2024-12-11 00:15","pubTimestamp":1733847307,"startTime":"0","endTime":"0","summary":"Brookline downgraded CervoMed (CRVO) to Hold from Buy and suspended the firm’s price target on the shares following the failure of the company’s Ph...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-downgraded-to-hold-from-buy-at-brookline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-downgraded-to-hold-from-buy-at-brookline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BRKL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cervomed.com","stockEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.806},{"period":"3month","weight":-0.8198},{"period":"6month","weight":-0.855},{"period":"1year","weight":-0.75},{"period":"ytd","weight":-0.0128}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":-0.0316},{"period":"3month","weight":0.0199},{"period":"6month","weight":0.0578},{"period":"1year","weight":0.2403},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.06704},{"month":2,"riseRate":0.625,"avgChangeRate":0.136561},{"month":3,"riseRate":0.5,"avgChangeRate":0.023523},{"month":4,"riseRate":0.375,"avgChangeRate":-0.070824},{"month":5,"riseRate":0.5,"avgChangeRate":0.190358},{"month":6,"riseRate":0.125,"avgChangeRate":-0.120544},{"month":7,"riseRate":0.125,"avgChangeRate":-0.126774},{"month":8,"riseRate":0.625,"avgChangeRate":0.065088},{"month":9,"riseRate":0.125,"avgChangeRate":-0.112535},{"month":10,"riseRate":0.125,"avgChangeRate":-0.028187},{"month":11,"riseRate":0.25,"avgChangeRate":-0.102922},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.206123}],"exchange":"NASDAQ","name":"CervoMed","nameEN":"CervoMed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CervoMed,CRVO,CervoMed股票,CervoMed股票老虎,CervoMed股票老虎国际,CervoMed行情,CervoMed股票行情,CervoMed股价,CervoMed股市,CervoMed股票价格,CervoMed股票交易,CervoMed股票购买,CervoMed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}